Teva to Present at the Morgan Stanley Annual Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced that Richard Francis, the President and CEO of Teva, will be speaking at the Morgan Stanley Annual Global Healthcare Conference. This presentation is scheduled for September 4, 2024, at 11:30 A.M. Eastern Time.
Webcast Information
If you're interested in watching the live presentation, you can find it on Teva’s Investor Relations website. An archived version will be made available shortly after the live event wraps up, ensuring that everyone can access the valuable insights shared during the discussion.
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a prominent player in the global pharmaceutical sector. The company is well-known for its extensive portfolio, which highlights its expertise in generic drugs while also pushing forward in innovative areas. With a legacy of over 120 years, Teva is dedicated to improving health outcomes through high-quality medications.
Global Presence and Workforce
Teva boasts a vast global network, employing around 37,000 individuals across 58 markets. This large workforce is motivated by a mission to drive scientific innovation, striving to provide quality medications that improve the health and lives of millions of patients every day.
Innovative Strategies and Commitment to Growth
The company is actively working on expanding its capabilities through its Pivot to Growth strategy. This initiative focuses on enhancing its pipeline of innovative and biosimilar medicines. Teva is dedicated to effectively commercializing its range of innovative and biosimilar products, ensuring patients have access to effective treatment options.
Challenges and Responsibilities
As Teva forges ahead with its innovations, it faces the challenges posed by intense competition in the pharmaceutical industry. The company is also managing significant financial responsibilities, including a considerable amount of debt. Teva remains committed to navigating these challenges through strategic business planning and adherence to regulatory requirements.
Investor Relations Contact Information
For any inquiries, Teva Pharmaceutical Industries Ltd. offers several contact points:
- Ran Meir: +1 (215) 591-8912
- Yael Ashman: +972 (3) 914 8262
- Sanjeev Sharma: +1 (973) 658 2700
- Kelley Dougherty: +1 (973) 832-2810
- Eden Klein: +972 (3) 906 2645
Frequently Asked Questions
What is the purpose of Teva's presentation at the Morgan Stanley conference?
The presentation aims to share insights about Teva's strategies, innovations, and commitments to healthcare improvements.
How can I access the live webcast of Teva's presentation?
The live webcast can be accessed through Teva’s Investor Relations website on the day of the presentation.
What is Teva's Pivot to Growth strategy?
This strategy focuses on expanding Teva's portfolio of innovative and biosimilar medicines to enhance its market presence.
How has Teva adapted to challenges in the pharmaceutical industry?
Teva continues to navigate competitive pressures and financial responsibilities by employing strategic business planning and focusing on regulatory compliance.
Where can I find more information about Teva Pharmaceutical Industries Ltd.?
Additional information is available on their official website, which provides insights into their products and corporate initiatives.